JNJ
Wall Street’s mood board just got a little brighter
Argus cranked its price target on Johnson & Johnson up to $275 from $240 and kept the stock at Buy. That’s basically Wall Street saying, “Same house, better lighting,” and it suggests about 16% upside from where the shares last closed.
Why investors care
Price-target hikes don’t magically mint cash, but they do matter because they help shape sentiment — and sentiment is half the stock market’s circus. J&J already has a pretty healthy chorus of bullish analysts around it, with the broader consensus sitting near a Moderate Buy and a price target around $251.52.
The fine print still matters
This isn’t a clean victory lap. The note also flags a few headaches that could cramp the stock’s style:
- biosimilar competition nibbling at the moat
- Stelara, the legacy drug star, losing some shine
- weaker free cash flow than investors would probably like
- insider share sales popping up in the quarter
The big picture
J&J is still one of those mega-cap names that investors treat like a dependable airport lounge: not flashy, but comfortable when the market gets bumpy. A higher target from Argus won’t erase the risks, but it does reinforce the idea that analysts think the stock still has some runway left.